Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?

Ribavirin was discovered nearly 40 years ago as a broad-spectrum antiviral drug. Recent data suggest that ribavirin may also be an effective cancer therapy. In this case, ribavirin targets an oncogene, the eukaryotic translation initiation factor eIF4E, elevated in approximately 30% of cancers including many leukemias and lymphomas. Specifically, ribavirin impedes eIF4E mediated oncogenic transformation by acting as an inhibitor of eIF4E. In a phase II clinical trial, ribavirin treatment led to substantial clinical benefit in patients with poor-prognosis acute myeloid leukemia (AML). Here molecular targeting of eIF4E correlated with clinical response. Ribavirin also targets a key enzyme in the guanosine biosynthetic pathway, inosine monophosphate dehydrogenase (IMPDH), and also modulates immunity. Parallels with known antiviral mechanisms could be informative; however, after 40 years, these are not entirely clear. The antiviral effects of ribavirin appear cell-type specific. This variation likely arises for many reasons, including cell specific variations in ribavirin metabolism as well as virus specific factors. Thus, it seems that the mechanisms for ribavirin action in cancer therapy may also vary in terms of the cancer/tissue under study. Here we review the anticancer activities of ribavirin and discuss the possible utility of incorporating ribavirin into diverse cancer therapeutic regimens.

[1]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[2]  R. K. Robins,et al.  Broad-Spectrum Antiviral Activity of Virazole: 1-f8- D-Ribofuranosyl- 1,2,4-triazole- 3-carboxamide , 1972, Science.

[3]  R. J. Bauer,et al.  Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. K. Robins,et al.  THE RELATIONSHIP BETWEEN THE METABOLISM OF RIBAVIRIN AND ITS PROPOSED MECHANISM OF ACTION , 1977, Annals of the New York Academy of Sciences.

[5]  D. Carson,et al.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T. Zimmerman,et al.  Metabolism of 5-amino-1-beta-D-ribofuranosylimidazole-4-carboxamide and related five-membered heterocycles to 5'-triphosphates in human blood and L5178Y cells. , 1978, Biochemical pharmacology.

[7]  R. Smith,et al.  The broad spectrum antiviral agent ribavirin inhibits capping of mRNA. , 1979, Biochemical and biophysical research communications.

[8]  B. K. Murray,et al.  Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent , 1983, Antimicrobial Agents and Chemotherapy.

[9]  W. Sadee,et al.  Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture. , 1985, Cancer research.

[10]  V. Marquez,et al.  Ribavirin, tiazofurin, and selenazofurin: mononucleotides and nicotinamide adenine dinucleotide analogues. Synthesis, structure, and interactions with IMP dehydrogenase. , 1985, Journal of medicinal chemistry.

[11]  D. Smee,et al.  Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells , 1986, Antimicrobial Agents and Chemotherapy.

[12]  G. Weber,et al.  Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase. , 1988, Biochemistry.

[13]  Y. Yamaji,et al.  Synergistic cytotoxic effect of tiazofurin and ribavirin in hepatoma cells. , 1988, Biochemical and biophysical research communications.

[14]  J. Connor,et al.  The metabolism of ribavirin in erythrocytes and nucleated cells. , 1990, The International journal of biochemistry.

[15]  M. Boosalis,et al.  Tiazofurin effects on IMP-dehydrogenase activity and expression in the leukemia cells of patients with CML blast crisis. , 1996, Anticancer research.

[16]  N. Sonenberg,et al.  Translational control of programmed cell death: eukaryotic translation initiation factor 4E blocks apoptosis in growth-factor-restricted fibroblasts with physiologically expressed or deregulated Myc , 1996, Molecular and cellular biology.

[17]  J. Stark,et al.  Inhibition of Viral Replication Reverses Respiratory Syncytial Virus-Induced NF-kB Activation and Interleukin-8 Gene Expression in A549 Cells , 1996 .

[18]  A. De Benedetti,et al.  Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma , 1997, Cancer.

[19]  Benjamin D. L. Li,et al.  Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer , 1997, Oncogene.

[20]  P. Glue,et al.  Ribavirin uptake by human erythrocytes and the involvement of nitrobenzylthioinosine‐sensitive (es)‐nucleoside transporters , 1998, British journal of pharmacology.

[21]  A. Gingras,et al.  The mRNA 5' cap-binding protein eIF4E and control of cell growth. , 1998, Current opinion in cell biology.

[22]  A. De Benedetti,et al.  Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. , 1998, Annals of Surgery.

[23]  P. Glue,et al.  The clinical pharmacology of ribavirin. , 1999, Seminars in liver disease.

[24]  C. Meschonat,et al.  Competitive PCR to detect eIF4E gene amplification in head and neck cancer , 1999, Head & neck.

[25]  A. De Benedetti,et al.  Progressive amplification and overexpression of the eukaryotic initiation factor 4E gene in different zones of head and neck cancers. , 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[26]  A. De Benedetti,et al.  Analysis of surgical margins with the molecular marker eIF4E: a prognostic factor in patients with head and neck cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  I. London,et al.  Upregulation of protein synthesis initiation factor eIF-4E is an early event during colon carcinogenesis , 1999, Oncogene.

[28]  B. Woda,et al.  Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin's lymphomas. , 1999, The American journal of pathology.

[29]  J. McCarthy,et al.  Stabilization of Eukaryotic Initiation Factor 4E Binding to the mRNA 5′-Cap by Domains of eIF4G* , 2000, The Journal of Biological Chemistry.

[30]  A. Harris,et al.  Eukaryotic initiation factor-4E in superficial and muscle invasive bladder cancer and its correlation with vascular endothelial growth factor expression and tumour progression , 1999, British Journal of Cancer.

[31]  N. Sonenberg,et al.  Inhibition of Myc-dependent apoptosis by eukaryotic translation initiation factor 4E requires cyclin D1 , 2000, Oncogene.

[32]  Roger Williams,et al.  Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. , 2000, Gastroenterology.

[33]  I. Rosenwald,et al.  Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma. , 2001, Thyroid : official journal of the American Thyroid Association.

[34]  A. Fraire,et al.  Expression of eukaryotic translation initiation factors 4E and 2α is increased frequently in bronchioloalveolar but not in squamous cell carcinomas of the lung , 2001, Cancer.

[35]  A. Kentsis,et al.  PML RING suppresses oncogenic transformation by reducing the affinity of eIF4E for mRNA , 2001, The EMBO journal.

[36]  A. Kentsis,et al.  The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. , 2001, Journal of molecular biology.

[37]  T. Pawełczyk,et al.  Expression level of adenosine kinase in rat tissues. Lack of phosphate effect on the enzyme activity. , 2001, Acta biochimica Polonica.

[38]  A. Kentsis,et al.  Control of biochemical reactions through supramolecular RING domain self-assembly , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[39]  I. Jacobs,et al.  A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer , 2002, British Journal of Cancer.

[40]  K. Borden,et al.  The emerging roles of translation factor eIF4E in the nucleus. , 2002, Differentiation; research in biological diversity.

[41]  Benjamin D. L. Li,et al.  Prospective Study of Eukaryotic Initiation Factor 4E Protein Elevation and Breast Cancer Outcome , 2002, Annals of surgery.

[42]  C. Cameron,et al.  Pleiotropic mechanisms of ribavirin antiviral activities. , 2002, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.

[43]  K. Eguchi,et al.  Expression of eukaryotic initiation factor 4E in atypical adenomatous hyperplasia and adenocarcinoma of the human peripheral lung. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  P. Pandolfi,et al.  Does the ribosome translate cancer? , 2003, Nature Reviews Cancer.

[45]  B. Chiang,et al.  Ribavirin or CpG DNA sequence-modulated dendritic cells decrease the IgE level and airway inflammation. , 2003, American journal of respiratory and critical care medicine.

[46]  M. Peterson,et al.  Translation Factor eIF4E Rescues Cells from Myc-dependent Apoptosis by Inhibiting Cytochromec Release* , 2003, The Journal of Biological Chemistry.

[47]  L. Yeh,et al.  Pharmacokinetics and Metabolism of [14C]Viramidine in Rats and Cynomolgus Monkeys , 2003, Antimicrobial Agents and Chemotherapy.

[48]  K. Borden,et al.  The proline‐rich homeodomain protein, PRH, is a tissue‐specific inhibitor of eIF4E‐dependent cyclin D1 mRNA transport and growth , 2003, The EMBO journal.

[49]  J. Licht,et al.  Aberrant Eukaryotic Translation Initiation Factor 4E-Dependent mRNA Transport Impedes Hematopoietic Differentiation and Contributes to Leukemogenesis , 2003, Molecular and Cellular Biology.

[50]  S. Lowe,et al.  Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy , 2004, Nature.

[51]  S. Zimmer,et al.  Translational control and metastatic progression: Enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs , 2004, Clinical & Experimental Metastasis.

[52]  T. Traut,et al.  Physiological concentrations of purines and pyrimidines , 1994, Molecular and Cellular Biochemistry.

[53]  Matthew J. Stephens,et al.  Global effect of PEG-IFN-alpha and ribavirin on gene expression in PBMC in vitro. , 2004, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[54]  King-Jen Chang,et al.  Expression of eukaryotic initiation factor 4E in gastric adenocarcinoma and its association with clinical outcome , 2004, Journal of surgical oncology.

[55]  B. Mitchell,et al.  Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part I. In vivo studies. , 2004, Leukemia research.

[56]  P. Glue,et al.  Intestinal Absorption of Ribavirin Is Preferentially Mediated by the Na+-Nucleoside Purine (Nl) Transporter , 1998, Pharmaceutical Research.

[57]  Matthew J. Stephens,et al.  Global effect of PEG-IFN-α and ribavirin on gene expression in PBMC in vitro , 2004 .

[58]  P. Pandolfi,et al.  The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis , 2004, Nature Medicine.

[59]  A. Kentsis,et al.  Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[60]  M. Boosalis,et al.  Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies. , 2004, Leukemia research.

[61]  Byoung-Gie Kim,et al.  eIF-4E expression is associated with histopathologic grades in cervical neoplasia. , 2005, Human pathology.

[62]  G. Caldito,et al.  eIF4E as a Marker for Cervical Neoplasia , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[63]  R. Lotan,et al.  Growth inhibition of head and neck squamous carcinoma cells by small interfering RNAs targeting eIF4E or cyclin D1 alone or combined with cisplatin , 2005, Cancer biology & therapy.

[64]  Combination of Nucleoside Analogues Tiazofurin and Ribavirin Downregulates Experimental Autoimmune Encephalomyelitis , 2005, Annals of the New York Academy of Sciences.

[65]  A. Kentsis,et al.  Further evidence that ribavirin interacts with eIF4E. , 2005, RNA.

[66]  A. Kentsis,et al.  Eukaryotic Translation Initiation Factor 4E Activity Is Modulated by HOXA9 at Multiple Levels , 2005, Molecular and Cellular Biology.

[67]  C. Meschonat,et al.  A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Positive Breast Cancer , 2005, Annals of surgery.

[68]  W. Parker,et al.  Metabolism and antiviral activity of ribavirin. , 2005, Virus research.

[69]  J. Wu,et al.  Phosphorylation of Ribavirin and Viramidine by Adenosine Kinase and Cytosolic 5′-Nucleotidase II: Implications for Ribavirin Metabolism in Erythrocytes , 2005, Antimicrobial Agents and Chemotherapy.

[70]  C. Meschonat,et al.  Detection of eIF4E gene amplification in breast cancer by competitive PCR , 1998, Annals of Surgical Oncology.

[71]  I. Kenessey,et al.  [Study of drugs against neoplastic metastasis]. , 2006, Magyar onkologia.

[72]  G. Weber.  Metabolic regulation and chemotherapy. , 2006, Advances in enzyme regulation.

[73]  C. Meschonat,et al.  High eIF4E, VEGF, and Microvessel Density in Stage I to III Breast Cancer , 2006, Annals of surgery.

[74]  K. Borden,et al.  eIF4E is a central node of an RNA regulon that governs cellular proliferation , 2006, The Journal of cell biology.

[75]  Tao Wang,et al.  Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. , 2007, The Journal of clinical investigation.

[76]  Takashi Yamamoto,et al.  Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. , 2007, European journal of pharmacology.

[77]  K. Borden,et al.  Controlling Gene Expression through RNA Regulons: The Role of the Eukaryotic Translation Initiation Factor eIF4E , 2007, Cell cycle.

[78]  C. Sarrazin,et al.  Viral Determinants of Resistance to Treatment in Patients with Hepatitis C , 2007, Clinical Microbiology Reviews.

[79]  S. Steinberg,et al.  Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. , 2007, Oncology reports.

[80]  C. Meschonat,et al.  A Prospective Trial on Initiation Factor 4E (eIF4E) Overexpression and Cancer Recurrence in Node-Negative Breast Cancer , 2008, Annals of Surgical Oncology.

[81]  B. Woda,et al.  Expression of the translation initiation factors eIF-4E and eIF-2* is frequently increased in neoplastic cells of Hodgkin lymphoma. , 2008, Human pathology.

[82]  K. Borden.  Pondering the puzzle of PML (promyelocytic leukemia) nuclear bodies: can we fit the pieces together using an RNA regulon? , 2008, Biochimica et biophysica acta.

[83]  K. Borden,et al.  The eIF4E RNA regulon promotes the Akt signaling pathway , 2008, The Journal of cell biology.

[84]  W. Weichert,et al.  Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. , 2008, Oncology reports.

[85]  K. Borden,et al.  Ribavirin targets eIF4E dependent Akt survival signaling. , 2008, Biochemical and biophysical research communications.

[86]  P. Gao,et al.  Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells , 2009, Breast Cancer Research and Treatment.

[87]  D. Lane,et al.  Crystallization of eIF4E complexed with eIF4GI peptide and glycerol reveals distinct structural differences around the cap-binding site , 2009, Cell cycle.

[88]  Long-Bang Chen,et al.  Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma. , 2009, Lung cancer.

[89]  J. Deddens,et al.  eIF4E activation is commonly elevated in advanced human prostate cancers and significantly related to reduced patient survival. , 2009, Cancer research.

[90]  T. Khoury,et al.  Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. , 2009, Clinical lung cancer.

[91]  B. Leber,et al.  Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. , 2009, Blood.

[92]  G. Rassidakis,et al.  Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper‐CVAD and rituximab, alternating with rituximab, high‐dose methotrexate, and cytarabine , 2009, Cancer.

[93]  S. Kondo,et al.  Adenovirus-mediated eukaryotic initiation factor 4E binding protein-1 in combination with rapamycin inhibits tumor growth of pancreatic ductal adenocarcinoma in vivo. , 2009, International journal of oncology.

[94]  K. Borden,et al.  Understanding and Targeting the Eukaryotic Translation Initiation Factor eIF4E in Head and Neck Cancer , 2009, Journal of oncology.

[95]  M. García-Villanueva,et al.  Eukaryotic Initiation Factors (eIF) 2α and 4E Expression, Localization, and Phosphorylation in Brain Tumors , 2009, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[96]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[97]  K. Borden,et al.  Structural characterization of the Z RING-eIF4E complex reveals a distinct mode of control for eIF4E , 2010, Proceedings of the National Academy of Sciences.

[98]  The metabolism , pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus , .